Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy

Stock News

9小時前

Antengene-B (06996) has announced a significant regulatory milestone, with its self-developed investigational drug ATG-201 receiving approval from the Australian Human Research Ethics Committee (HREC) for the Phase I ATTRACT study.

ATG-201 is a CD19/CD3 bispecific T-cell engager antibody designed to target B-cell mediated autoimmune diseases, marking an important step forward in the company's clinical development pipeline.

The company's board confirmed that in addition to the HREC approval, the clinical trial notification (CTN) submission process with the Therapeutic Goods Administration (TGA) has also been completed, paving the way for the trial's initiation in Australia.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1179996720"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179996720\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179996720?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-25 07:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179996720","market":"nz","top_or_hot":-1,"title":"Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy","media":"Stock News","content":"<p><b>Antengene-B</b> (<b>06996</b>) has announced a significant regulatory milestone, with its self-developed investigational drug ATG-201 receiving approval from the Australian Human Research Ethics Committee (HREC) for the Phase I ATTRACT study.<br><br>ATG-201 is a CD19/CD3 bispecific T-cell engager antibody designed to target B-cell mediated autoimmune diseases, marking an important step forward in the company's clinical development pipeline.<br><br>The company's board confirmed that in addition to the HREC approval, the clinical trial notification (CTN) submission process with the Therapeutic Goods Administration (TGA) has also been completed, paving the way for the trial's initiation in Australia.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAntengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-08-25 07:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><b>Antengene-B</b> (<b>06996</b>) has announced a significant regulatory milestone, with its self-developed investigational drug ATG-201 receiving approval from the Australian Human Research Ethics Committee (HREC) for the Phase I ATTRACT study.<br><br>ATG-201 is a CD19/CD3 bispecific T-cell engager antibody designed to target B-cell mediated autoimmune diseases, marking an important step forward in the company's clinical development pipeline.<br><br>The company's board confirmed that in addition to the HREC approval, the clinical trial notification (CTN) submission process with the Therapeutic Goods Administration (TGA) has also been completed, paving the way for the trial's initiation in Australia.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物醫藥B類股","start_time":0,"source_url":"","article_id":"1179996720","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179996720","pubTimestamp":1787612662,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Antengene-B (06996) has announced a significant regulatory milestone, with its self-developed investigational drug ATG-201 receiving approval from the Australian Human Research Ethics Committee...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1191":"制药","06996":"德琪医药-B","BK1583":"高瓴概念"},"translate_title":"Antengene 的 ATG-201 I 期 ATTRACT 试验获得澳大利亚伦理委员会批准用于 B 细胞自身免疫性疾病治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06996":1},"content_text":"Antengene-B (06996) has announced a significant regulatory milestone, with its self-developed investigational drug ATG-201 receiving approval from the Australian Human Research Ethics Committee (HREC) for the Phase I ATTRACT study.ATG-201 is a CD19/CD3 bispecific T-cell engager antibody designed to target B-cell mediated autoimmune diseases, marking an important step forward in the company's clinical development pipeline.The company's board confirmed that in addition to the HREC approval, the clinical trial notification (CTN) submission process with the Therapeutic Goods Administration (TGA) has also been completed, paving the way for the trial's initiation in Australia.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}